Cargando…

脾边缘区淋巴瘤患者IGHV突变状态分析

OBJECTIVE: To investigate the IGHV mutational status and its differences from Caucasian in splenic marginal zone lymphoma (SMZL). METHODS: A retrospective study on 40 SMZL cases were performed to detect the V-D-J sequence of IGHV by plasmid cloning sequencing, comparing the data with the most homolo...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342109/
https://www.ncbi.nlm.nih.gov/pubmed/27719720
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.09.009
_version_ 1783555367873019904
collection PubMed
description OBJECTIVE: To investigate the IGHV mutational status and its differences from Caucasian in splenic marginal zone lymphoma (SMZL). METHODS: A retrospective study on 40 SMZL cases were performed to detect the V-D-J sequence of IGHV by plasmid cloning sequencing, comparing the data with the most homologous germ line V sequence in database, identifying the stereotype of patients through cluster analysis and alignment. The clinical and laboratory characteristics were compared between the patients with IGHV mutation and without mutations. RESULTS: In SMZL patients, the proportion of IGHV mutations was 75%, consistent with data from Caucasian. In V region, the usage of V3-23 subtype was lower in Chinese patients compared with Caucasian (2.6% vs 18.0%, P=0.006), whereas the V2-70 subtype was used with high proportion (10.3% vs 0.8%, P=0.002). In D region, the D2-21 and D6-13 gene were used frequently (17.9% vs 2.3%, P<0.001; 12.8% vs 3.8%, P=0.046). One new stereotype was found, and the SMZL-biased V1-2 gene was mostly used (25.6%). The levels of IgG and IgA were significantly increased in IGHV without mutations as compared with mutations [10.70 (5.28–15.50) g/L vs 12.90 (7.71–23.50) g/L, 1.06 (0.21–3.13) g/L vs 1.66 (0.81–2.93) g/L, P=0.038, 0.040]. The only two 17p deletion patients were IGHV without mutaions. The progression free survival (PFS) was significantly prolonged in IGHV mutations (P=0.009), and there was no significant difference regarding to the overall survival between the two subgroups (P=0.430). CONCLUSION: The proportion of IGHV mutaions was similar to the data in Caucasian. There was disparity in the usage of V and D regions between Chinese and Caucasian, and the SMZL-biased V1-2 gene were used more frequently in Chinese patients. One new stereotype was identified. In the IGHV without mutations group, the levels of IgG and IgA were significantly increased.
format Online
Article
Text
id pubmed-7342109
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73421092020-07-16 脾边缘区淋巴瘤患者IGHV突变状态分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To investigate the IGHV mutational status and its differences from Caucasian in splenic marginal zone lymphoma (SMZL). METHODS: A retrospective study on 40 SMZL cases were performed to detect the V-D-J sequence of IGHV by plasmid cloning sequencing, comparing the data with the most homologous germ line V sequence in database, identifying the stereotype of patients through cluster analysis and alignment. The clinical and laboratory characteristics were compared between the patients with IGHV mutation and without mutations. RESULTS: In SMZL patients, the proportion of IGHV mutations was 75%, consistent with data from Caucasian. In V region, the usage of V3-23 subtype was lower in Chinese patients compared with Caucasian (2.6% vs 18.0%, P=0.006), whereas the V2-70 subtype was used with high proportion (10.3% vs 0.8%, P=0.002). In D region, the D2-21 and D6-13 gene were used frequently (17.9% vs 2.3%, P<0.001; 12.8% vs 3.8%, P=0.046). One new stereotype was found, and the SMZL-biased V1-2 gene was mostly used (25.6%). The levels of IgG and IgA were significantly increased in IGHV without mutations as compared with mutations [10.70 (5.28–15.50) g/L vs 12.90 (7.71–23.50) g/L, 1.06 (0.21–3.13) g/L vs 1.66 (0.81–2.93) g/L, P=0.038, 0.040]. The only two 17p deletion patients were IGHV without mutaions. The progression free survival (PFS) was significantly prolonged in IGHV mutations (P=0.009), and there was no significant difference regarding to the overall survival between the two subgroups (P=0.430). CONCLUSION: The proportion of IGHV mutaions was similar to the data in Caucasian. There was disparity in the usage of V and D regions between Chinese and Caucasian, and the SMZL-biased V1-2 gene were used more frequently in Chinese patients. One new stereotype was identified. In the IGHV without mutations group, the levels of IgG and IgA were significantly increased. Editorial office of Chinese Journal of Hematology 2016-09 /pmc/articles/PMC7342109/ /pubmed/27719720 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.09.009 Text en 2016年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
脾边缘区淋巴瘤患者IGHV突变状态分析
title 脾边缘区淋巴瘤患者IGHV突变状态分析
title_full 脾边缘区淋巴瘤患者IGHV突变状态分析
title_fullStr 脾边缘区淋巴瘤患者IGHV突变状态分析
title_full_unstemmed 脾边缘区淋巴瘤患者IGHV突变状态分析
title_short 脾边缘区淋巴瘤患者IGHV突变状态分析
title_sort 脾边缘区淋巴瘤患者ighv突变状态分析
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342109/
https://www.ncbi.nlm.nih.gov/pubmed/27719720
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.09.009
work_keys_str_mv AT píbiānyuánqūlínbāliúhuànzhěighvtūbiànzhuàngtàifēnxī
AT píbiānyuánqūlínbāliúhuànzhěighvtūbiànzhuàngtàifēnxī
AT píbiānyuánqūlínbāliúhuànzhěighvtūbiànzhuàngtàifēnxī
AT píbiānyuánqūlínbāliúhuànzhěighvtūbiànzhuàngtàifēnxī
AT píbiānyuánqūlínbāliúhuànzhěighvtūbiànzhuàngtàifēnxī
AT píbiānyuánqūlínbāliúhuànzhěighvtūbiànzhuàngtàifēnxī
AT píbiānyuánqūlínbāliúhuànzhěighvtūbiànzhuàngtàifēnxī
AT píbiānyuánqūlínbāliúhuànzhěighvtūbiànzhuàngtàifēnxī
AT píbiānyuánqūlínbāliúhuànzhěighvtūbiànzhuàngtàifēnxī